United Kingdom
Industry
BMI View: The design of drugs - both visual and in terms of their administration - will become an increasingly important facet of the drug development process, as the value of a medicine...
2012-01-17Industry
BMI View: The importance of maintaining healthy research and development (R&D) pipelines and launching new drugs by innovative drugmakers cannot be stressed enough. The patent cliff...
2012-01-12Industry
BMI View: The importance of maintaining healthy research and development (R&D) pipelines and launching new drugs by innovative drugmakers cannot be stressed enough. The patent cliff...
2011-12-21Industry
BMI View: While the local pharmaceutical industry does not employee a large proportion of the UK labour force, the closure of sites by multinational drugmakers during the economic slowdown...
2011-12-12Industry
BMI View: We welcome the government's recognition of the benefits of telecare in providing out-patient care as we believe that in the long run, investment in the technology will work...
2011-12-08Industry
BMI View: AstraZeneca's Q311 results highlight its high exposure to healthcare sector cost-containment programmes and pricing pressures placed on medicines by governments in developed...
2011-10-28Industry
BMI View: GlaxoSmithKline (GSK)'s Q311 results illustrate its high exposure to healthcare sector cost-containment programmes, but we believe the company's identification of the different...
2011-10-27Industry
BMI View: The increase in the dental patient charge in the UK in treatment bands 2 and 3, which include more complex treatments, highlights the increased use of interventions, which...
2011-09-27
